Tyrosine Kinase Inhibitors: all 10,744 studies that test it

Page 90 of 108. Open to participants first (1,949), then studies with results posted, then the rest; newest registration first within each.

• Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver CancerCompletedNCT01624285Phase 2
• Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular CarcinomaWithdrawnNCT01618253Phase 1
• A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2CompletedNCT01614522Phase 2
• Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)CompletedNCT01613846Phase 3
• Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian CancerCompletedNCT01610869Phase 2
• Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin LymphomaTerminatedNCT01609816Phase 1
• The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without ErlotinibStatus unknownNCT01608841Phase 2
• A Single and Multiple Dose Study to Assess Blood and Urine Drug Levels of Fostamatinib in Healthy Japanese SubjectsCompletedNCT01608542Phase 1
• Study of Curcumin, Vorinostat, and SorafenibWithdrawnNCT01608139Phase 1
• [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian CancerCompletedNCT01608009Phase 1
• Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.WithdrawnNCT01605981Phase 4
• A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid MalignanciesSuspendedNCT01604863Phase 1
• Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKICompletedNCT01602952Phase 1/2
• A Study of LY2875358 in Japanese Participants With Advanced CancerCompletedNCT01602289Phase 1
• Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic CarcinomaCompletedNCT01601808Phase 2
• OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the PancreasWithdrawnNCT01600807Phase 1/2
• A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib TherapyCompletedNCT01599949Phase 2
• Tofacitinib Bioequivalence Study Comparing Tablets And CapsulesCompletedNCT01599377Phase 1
• Study in Healthy Males to Assess Bioavailability of Single Fostamatinib With iv Micro Tracer DoseCompletedNCT01598571Phase 1
• A Study of JNJ-40346527 in Patients With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug TherapyCompletedNCT01597739Phase 2
• Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid TumorsCompletedNCT01596647Phase 1
• A Study of LY2784544 in Participants With Myeloproliferative NeoplasmsActive, not recruitingNCT01594723Phase 2
• Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing ChemotherapyCompletedNCT01594177Phase 2
• 24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking MethotrexateCompletedNCT01590459Phase 2
• Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast CancerTerminatedNCT01589861Phase 1/2
• A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic RetinopathyWithdrawnNCT01589718Phase 3
• Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC PatientsCompletedNCT01588145Phase 1/2
• Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in CombinationCompletedNCT01585870Phase 1
• Drug Interaction Study of SAR302503 in Patients With Solid TumorCompletedNCT01585623Phase 1
• Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard TherapyCompletedNCT01584830Phase 3
• Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian CancerCompletedNCT01583322Phase 2
• XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone DiseaseCompletedNCT01582295Phase 1
• ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung CancerCompletedNCT01580735Phase 2
• Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML PatientsCompletedNCT01578213Phase 4
• Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid LeukemiaCompletedNCT01578109Phase 1
• Pazopanib in Second-line Therapy in Renal Cell CarcinomaStatus unknownNCT01577784Phase 2
• A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma PatientsCompletedNCT01576380Phase 2
• XL-184+Abiraterone in Post-Chemo CRPCCompletedNCT01574937Phase 1
• Safety Study of AKN-028 in Patients With Acute Myelogenous LeukemiaTerminatedNCT01573247Phase 1/2
• A Study To Compare Pharmacokinetics Of Dacomitinib (PF-00299804) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic ImpairmentCompletedNCT01571388Phase 1
• A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFRCompletedNCT01570296Phase 1
• Imatinib and Carvedilol for High Blood Pressure in the Lungs in Adults With Sickle Cell DiseaseWithdrawnNCT01568645Phase 1
• A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor MalignanciesWithdrawnNCT01567384Phase 1
• Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5CompletedNCT01566747Phase 2
• A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid ArthritisCompletedNCT01565655Phase 2
• A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent GlioblastomaCompletedNCT01562197Phase 2
• Study in Healthy Volunteers to Assess the Pharmacokinetics (PK) of Digoxin Administered Alone and in Combination With VandetanibCompletedNCT01561781Phase 1
• Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the LungCompletedNCT01561456Phase 2
• Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal JunctionCompletedNCT01561014Phase 1
• Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFRCompletedNCT01556191Phase 2
• A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to MethotrexateCompletedNCT01554696Phase 2
• Afatinib With CT and RT for EGFR-Mutant NSCLCActive, not recruitingNCT01553942Phase 2
• Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced CancerCompletedNCT01553656Phase 1
• Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid TumorsActive, not recruitingNCT01552356Phase 1
• A Phase I Study to Assess the Pharmacokinetics of Metformin When Administered Alone and in Combination With VandetanibCompletedNCT01551615Phase 1
• A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal MelanomaCompletedNCT01551459Phase 2
• Drug Drug Interaction Study Of Crizotinib With Esomeprazole.CompletedNCT01549574Phase 1
• Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid TumorsTerminatedNCT01548924Phase 1
• To Assess the Interaction Between Sunitinib and Ketoconazole to Reduce the Dose and Cost of SunitinibCompletedNCT01548170Phase 1
• Pazopanib or Pemetrexed and Crizotinib in Advanced CancerTerminatedNCT01548144Phase 1
• A Phase I Study of INC280 in Japanese Patients With Advanced Solid TumorsCompletedNCT01546428Phase 1
• Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung CancerCompletedNCT01545947Phase 1
• Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse SclerodermaTerminatedNCT01545427Phase 2
• Study in Healthy Volunteers to Assess the Pharmacokinetics of Midazolam Administered Alone and in Combination With VandetanibCompletedNCT01544140Phase 1
• Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue SarcomaTerminatedNCT01543802Phase 2
• Effects of Curcumin on Vascular ReactivityCompletedNCT01543386Phase 1/2
• Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung CancerCompletedNCT01542437Phase 2
• A Combination of Pazopanib and Carboplatin in Advanced Solid MalignanciesTerminatedNCT01542047Phase 1
• Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDIActive, not recruitingNCT01541709Phase 2
• Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose AxitinibCompletedNCT01540526Phase 1
• Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)CompletedNCT01540461Phase 1
• Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of VandetanibCompletedNCT01539655Phase 1
• Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACETerminatedNCT01539018Phase 2
• Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and NeckCompletedNCT01538381Phase 2
• pazopanib_NCRCC,Ph2 STUDYCompletedNCT01538238Phase 2
• Nilotinib in PH+, BCR-, ABL+ CML PatientsCompletedNCT01535391Phase 3
• Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal CarcinomaCompletedNCT01534585Phase 1/2
• Erlotinib in Combination With Pralatrexate in Advanced MalignanciesCompletedNCT01532011Phase 1
• Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib in the Treatment of Advanced Colorectal CancerCompletedNCT01531777Phase 2
• BIBW 2992 (Afatinib) and VinorelbineTerminatedNCT01531764Phase 2
• Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially ResectableTerminatedNCT01531712Phase 2
• Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF MutationsCompletedNCT01531361Phase 1
• A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the BodyCompletedNCT01529684Phase 1
• Study of Axitinib and Temsirolimus in Solid TumorsCompletedNCT01529138Phase 1
• Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaCompletedNCT01528085Phase 2
• A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast CancerCompletedNCT01526369Phase 3
• Assessment of Blood Glucose Changes in Healthy Volunteers After BMS-754807 Alone or BMS-754807 With MetforminCompletedNCT01525823Phase 1
• A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc IntervalCompletedNCT01525394Phase 1
• CREATE: Cross-tumoral Phase 2 With CrizotinibCompletedNCT01524926Phase 2
• Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and SunitinibCompletedNCT01524848Phase 2
• First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell CarcinomaCompletedNCT01521715Phase 4
• Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative NeoplasmsCompletedNCT01520220Phase 1
• Whole Brain Radiation With or Without Erlotinib for Brain Metastases From Non-Small Cell Lung CancerTerminatedNCT01518621Phase 2
• Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid TumorsCompletedNCT01518413Phase 1
• Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer SubjectsCompletedNCT01517399Phase 1
• Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR MutationCompletedNCT01516983Phase 1/2
• Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)TerminatedNCT01515969Phase 1
• Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell CarcinomaCompletedNCT01515137Phase 1
• Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung CancerCompletedNCT01514877Phase 2
• Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical CarcinomaCompletedNCT01514526Phase 2

← Tyrosine Kinase Inhibitors overview